Lyka Labs Ltd. Share Price & Stock Analysis

Lyka Labs Ltd. (NSE: LYKALABS, BSE: 500259) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹294 Cr, it ranks #2,346 by market cap among the 6,197 Indian listed companies on FinBizNet, and #54 of 86 in Medicinal Chemicals and Botanical Products. At ₹84.62 (as of 16 Nov 2026), the share price is 5.3% below its 52-week high of ₹89.40 and 91.9% above its 52-week low of ₹44.10. The share price is down 9.6% over one year and up 24.4% over three months.

Key Metrics

Current Price₹84.62
Market Cap₹294 Cr
NSE SymbolLYKALABS
BSE Code500259
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E RatioNot meaningful (loss)
Return on Equity-10.74%
Return on Assets-4.25%
52-Week Range₹44.10 – ₹89.40
1-Year Price Change-9.6%
3-Month Price Change+24.4%
Beta (1Y)0.1
HeadquartersMumbai, Maharashtra
Websitewww.lykalabs.com

Latest Quarterly Results — Q2 FY27

Revenue₹44 Cr
Net Profit₹1 Cr
Net Margin2.9%
EPS (Basic)₹0.36
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Lyka Labs Ltd. Quarterly Revenue and Profit Trend

Lyka Labs Ltd. reported revenue of ₹44 Cr in Q2 FY27, up 20.6% from ₹37 Cr in Q2 FY26 and up 4.5% from ₹42 Cr in Q1 FY27. It posted a net profit of ₹1 Cr for the quarter, against a net loss of ₹3 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹28 Cr (Q4 FY26) to ₹44 Cr (Q2 FY27). The company reported a net loss in 3 of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹44 Cr₹1 Cr2.9%
Q1 FY27₹42 Cr₹2 Cr4.8%
Q4 FY26₹28 Cr−₹8 Cr−28.8%
Q3 FY26₹31 Cr−₹0 Cr−0.5%
Q2 FY26₹37 Cr−₹3 Cr−8.8%
Q1 FY26₹33 Cr₹1 Cr3.0%
Q4 FY25₹33 Cr₹2 Cr6.1%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 58.45% of Lyka Labs Ltd.'s shares as of Sept 2026, against 58.16% in Sept 2025 (+0.29 percentage points).

About Lyka Labs Ltd.

Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, anti-fungal and bacterial, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports it

Products and Services

1. Pharmaceuticals-This segment provides pharmaceutical products and pharma related services.

Business Segments

1. Pharmaceuticals-100%

Lyka Labs Ltd. vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Lyka Labs Ltd.₹294 Crn/m-10.74%₹44 Cr-9.6%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Lyka Labs Ltd.?

Lyka Labs Ltd. is trading at ₹84.62, with a market capitalisation of ₹294 Cr.

Which sector does Lyka Labs Ltd. belong to?

Lyka Labs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Lyka Labs Ltd.?

Lyka Labs Ltd. has a return on equity of -10.74%.

What is the stock symbol of Lyka Labs Ltd.?

Lyka Labs Ltd. is listed on the NSE under the symbol LYKALABS and on the BSE under the scrip code 500259.

How has Lyka Labs Ltd.'s share price moved over the past year?

Lyka Labs Ltd.'s share price is down 9.6% over one year and up 24.4% over three months. Its 52-week range is ₹44.10 to ₹89.40.

What were Lyka Labs Ltd.'s latest quarterly results?

In Q2 FY27, Lyka Labs Ltd. reported revenue of ₹44 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.36 (consolidated, parsed from the company's exchange filing).

How have Lyka Labs Ltd.'s revenue and profit changed over the past year?

Lyka Labs Ltd. reported revenue of ₹44 Cr in Q2 FY27, up 20.6% from ₹37 Cr in Q2 FY26 and up 4.5% from ₹42 Cr in Q1 FY27.

What is the promoter holding in Lyka Labs Ltd.?

Promoters held 58.45% of Lyka Labs Ltd.'s shares as of Sept 2026, against 58.16% in Sept 2025 (+0.29 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.